Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 3/20 | 0.44 |
| ▸ | CCR2 | P41597 | 1/20 | 0.43 |
| ▸ | PTGES2 | Q9H7Z7 | 6/20 | 0.42 |
| ▸ | CCR9 | P51686 | 6/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12096791 | 0.80 | HSD17B2 (0.46) | HSD17B2CCR9 | |
| SCHEMBL2227371 | 0.79 | AKT1 (0.45) | HSD17B2CCR2CCR9 | |
| SCHEMBL16798528 | 0.78 | CCR2 (0.43) | HSD17B2CCR2PTGES2CCR9 | |
| SCHEMBL12096937 | 0.77 | HSD17B2 (0.52) | HSD17B2PTGES2 | |
| SCHEMBL12096762 | 0.76 | PTGES2 (0.43) | HSD17B2CCR2PTGES2 | |
| SCHEMBL1714365 | 0.75 | MEN1 (0.53) | HSD17B2CCR2PTGES2 | |
| SCHEMBL2225526 | 0.74 | SLC40A1 (0.50) | HSD17B2CCR2PTGES2 | |
| SCHEMBL13852821 | 0.73 | PKM (0.56) | HSD17B2CCR9 | |
| SCHEMBL12096829 | 0.72 | MEN1 (0.53) | HSD17B2CCR2PTGES2 | |
| SCHEMBL13852835 | 0.72 | HSD17B2 (0.57) | HSD17B2CCR2PTGES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120232070-A1 | Use of Indole Derivatives as Nurr-1 Activators for the Application Thereof as a Medicament for the Treatment of Parkinson's Disease | LABORATOIRES FOURNIER SA (FR) | 2012-09-13 | — | — | US | disclosed |
| EP-2475642-A1 | USE OF INDOLE DERIVATIVES AS NURR-1 ACTIVATORS FOR THE APPLICATION THEREOF AS A MEDICAMENT FOR THE TREATMENT OF PARKINSON'S DISEASE | Laboratoires Fournier S.A. (FR) | 2012-07-18 | — | — | EP | disclosed |
| WO-2011030068-A1 | USE OF INDOLE DERIVATIVES AS NURR-1 ACTIVATORS FOR THE APPLICATION THEREOF AS A MEDICAMENT FOR THE TREATMENT OF PARKINSON'S DISEASE | LABORATOIRES FOURNIER SA (FR) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232070-A1 | Use of Indole Derivatives as Nurr-1 Activators for the Application Thereof as a Medicament for the Treatment of Parkinson's Disease | NCOR1, NR0B1, MTNR1A | HSD17B2 2537/4885CCR2 729/4885PTGES2 2493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.